DLBCL
Conditions
Interventions
single arm:Rituximab plus Lenalidomide
Sponsors
Anhui Provincial Cance Hospital
Eligibility
Sex/Gender
All
Age
70 Years to 100 Years
Inclusion criteria
Inclusion criteria: 1. Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification). DLBCL with some small cell infiltration in bone marrow or lymph node may be included. 2. Aged 80 to 70 years and ECOG >= 2. 3. With a minimum life expectancy of 3 months. 4. There is at least one imaging measurable lesion. 5. Having previously signed a written informed consent.
Exclusion criteria
Exclusion criteria: 1. Any other histological type of lymphoma. a. Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma. b. Any history of treated or non-treated indolent lymphoma. 2. Central nervous system or meningeal involvement by lymphoma. 3. Major surgical procedures were performed within 14 days of treatment of DLBCL. 4. Severe and uncontrolled cardiovascular disease. 5. Poor bone marrow reserve as defined by neutrophils 2 fold ULN). 7. Poor hepatic function (total bilirubin level > 2 fold ULN, transaminases > 3 fold ULN) unless these abnormalities are related to the lymphoma. 8. Uncontrolled and active systemic fungi, bacteria, viruses or other infections. 9. HIV infection. 10. Uncontrolled and active HBV and HCV infection. 11. Situations that investigator found it inappropriate to join this trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| OS; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;best ORR; | — |
Countries
China
Contacts
Public ContactDing Kai Yang
Anhui Provincial Cance Hospital
Outcome results
None listed